Although Merck Serono S.A. decided to drop Parkinson's disease from its neuroscience portfolio, its preclinical compounds targeting metabotropic glutamate receptors for PD will continue to live on in a newco called Prexton Therapeutics S.A.

Backed by Merck Serono's newly established spinout fund, Prexton hopes to generate proof-of-principle data for the molecules over the next year to attract external venture investors for a series A round.